FDA approves generic topical parasiticide for cats

June 2, 2020
dvm360 Staff
dvm360, dvm360 June 2020, Volume 51, Issue 6

Imoxi Topical Solution for Cats provides protection against some of the most common internal and external parasites.

The FDA has approved Vetoquinol’s Imoxi Topical Solution for Cats, the first generic version of a topical imidacloprid and moxidectin product, according to the FDA website.

Imoxi Topical Solution for Cats, which is available by prescription only, prevents heartworm disease caused by Dirofilaria immitis, kills adult fleas (Ctenocephalides felis) and treats and controls flea infestations and ear mite (Otodectes cynotis) infestations. It also protects against adult, immature adult, and fourth-stage larvae in hookworms (Ancylostoma tubaeforme) and adult and fourth-stage larvae in roundworms (Toxocara cati).

According to the FDA, this product contains the same concentration and dose of imidacloprid and moxidectin as the brand name drug product, Advantage Multi for Cats, which was approved in 2007. Imoxi Topical Solution for Dogs was approved in December 2019.

The newly approved drug contains no inactive ingredients that may significantly affect the bioavailability of the active ingredients, says the federal agency.

Click here for more information about this product.

download issueDownload Issue : dvm360 June 2020